{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:16:06Z","timestamp":1790511366744,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["\"Ricerca Corrente\""],"award-info":[{"award-number":["\"Ricerca Corrente\""]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FTLDc O1GI1007A"],"award-info":[{"award-number":["FTLDc O1GI1007A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["SOPHIA (01ED1202A), BiomarkAPD (01ED1203F) and Prefrontals (01ED1512)"],"award-info":[{"award-number":["SOPHIA (01ED1202A), BiomarkAPD (01ED1203F) and Prefrontals (01ED1512)"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In neurodegenerative dementias (NDs) such as prion disease, Alzheimer\u2019s disease (AD), and frontotemporal lobar degeneration (FTLD), protein misfolding leads to the tissue deposition of protein aggregates which, in turn, trigger neuroinflammation and neurodegeneration. Cerebrospinal fluid (CSF) biomarkers have the potential to reflect different aspects of these phenomena across distinct clinicopathological subtypes and disease stages.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We investigated CSF glial markers, namely chitotriosidase 1 (CHIT1), chitinase-3-like protein 1 (YKL-40) and glial fibrillary acidic protein (GFAP) in prion disease subtypes (<jats:italic>n<\/jats:italic>\u2009=\u2009101), AD (<jats:italic>n<\/jats:italic>\u2009=\u200940), clinicopathological subgroups of FTLD (<jats:italic>n<\/jats:italic>\u2009=\u200972), and controls (<jats:italic>n<\/jats:italic>\u2009=\u200940) using validated, commercially available ELISA assays. We explored glial biomarker levels\u2019 associations with disease variables and neurodegenerative CSF biomarkers and evaluated their diagnostic accuracy. The genotype of the <jats:italic>CHIT1<\/jats:italic> rs3831317 polymorphic site was also analyzed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Each ND group showed increased levels of CHIT1, YKL-40, and GFAP compared to controls with a difference between prion disease and AD or FTLD limited to YKL-40, which showed higher values in the former group. CHIT1 levels were reduced in both heterozygotes and homozygotes for the <jats:italic>CHIT1<\/jats:italic> 24-bp duplication (rs3831317) in FTLD and controls, but this effect was less significant in AD and prion disease. After stratification according to molecular subgroups, we demonstrated (i) an upregulation of all glial markers in Creutzfeldt-Jakob disease VV2 compared to other disease subtypes, (ii) a difference in CHIT1 levels between FTLD with TAU and TDP43 pathology, and (iii) a marked increase of YKL-40 in FTLD with amyotrophic lateral sclerosis (ALS) in comparison with FTLD without ALS. In prion disease, glial markers correlated with disease stage and were already elevated in one pre-symptomatic case of Gerstmann-Str\u00e4ussler-Scheinker disease. Regarding the diagnostic value, YKL-40 was the only glial marker that showed a moderate accuracy in the distinction between controls and NDs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>NDs share a CSF profile characterized by increased levels of CSF CHIT1, YKL-40, and GFAP, which likely reflects a common neuroinflammatory response to protein misfolding and aggregation. CSF glial markers of neuroinflammation demonstrate limited diagnostic value but have some potential for monitoring the clinical and, possibly, preclinical phases of NDs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13195-019-0562-4","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T09:02:24Z","timestamp":1577782944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia"],"prefix":"10.1186","volume":"12","author":[{"given":"Samir","family":"Abu-Rumeileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Polischi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mammana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bartoletti-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Zenesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Capellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-9524","authenticated-orcid":false,"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"issue":"2","key":"562_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bpa.12695","volume":"29","author":"S Baiardi","year":"2019","unstructured":"Baiardi S, Rossi M, Capellari S, Parchi P. Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol. 2019;29(2):278\u2013300. https:\/\/doi.org\/10.1111\/bpa.12695.","journal-title":"Brain Pathol"},{"issue":"4","key":"562_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469\u201391. https:\/\/doi.org\/10.1007\/s00401-014-1380-1.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"562_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bpa.12486","volume":"27","author":"DMA Mann","year":"2017","unstructured":"Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723\u201336. https:\/\/doi.org\/10.1111\/bpa.12486.","journal-title":"Brain Pathol"},{"issue":"3","key":"562_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3233\/JAD-171181","volume":"63","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Capellari S, Parchi P. Rapidly progressive Alzheimer\u2019s disease: contributions to clinical-pathological definition and diagnosis. J Alzheimers Dis. 2018;63(3):887\u201397. https:\/\/doi.org\/10.3233\/JAD-171181.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"562_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0.","journal-title":"Lancet Neurol"},{"issue":"10","key":"562_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/01.jnen.0000183346.19447.55","volume":"64","author":"G Puoti","year":"2005","unstructured":"Puoti G, Giaccone G, Mangieri M, Limido L, Fociani P, Zerbi P, et al. Sporadic Creutzfeldt-Jakob disease: the extent of microglia activation is dependent on the biochemical type of PrPSc. J Neuropathol Exp Neurol. 2005;64(10):902\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"562_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/nan.12092","volume":"40","author":"SB Lant","year":"2014","unstructured":"Lant SB, Robinson AC, Thompson JC, Rollinson S, Pickering-Brown S, Snowden JS, et al. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2014;40(6):686\u201396. https:\/\/doi.org\/10.1111\/nan.12092.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"562_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5.","journal-title":"Lancet Neurol"},{"issue":"9","key":"562_CR9","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1172\/JCI90607","volume":"127","author":"D Lall","year":"2017","unstructured":"Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017;127(9):3250\u20138. https:\/\/doi.org\/10.1172\/JCI90607.","journal-title":"J Clin Invest"},{"key":"562_CR10","doi-asserted-by":"publisher","unstructured":"Wang S, Colonna M. Microglia in Alzheimer\u2019s disease: a target for immunotherapy. J Leukoc Biol. 2019. https:\/\/doi.org\/10.1002\/JLB.MR0818-319R.","DOI":"10.1002\/JLB.MR0818-319R"},{"issue":"6","key":"562_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/nan.12461","volume":"44","author":"A Franceschini","year":"2018","unstructured":"Franceschini A, Strammiello R, Capellari S, Giese A, Parchi P. Regional pattern of microgliosis in sporadic Creutzfeldt-Jakob disease in relation to phenotypic variants and disease progression. Neuropathol Appl Neurobiol. 2018;44(6):574\u201389. https:\/\/doi.org\/10.1111\/nan.12461.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4\u20135","key":"562_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000474940","volume":"17","author":"L D\u2019Anna","year":"2017","unstructured":"D\u2019Anna L, Abu-Rumeileh S, Fabris M, Pistis C, Baldi A, Sanvilli N, et al. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients. Neurodegener Dis. 2017;17(4\u20135):227\u201334. https:\/\/doi.org\/10.1159\/000474940.","journal-title":"Neurodegener Dis"},{"issue":"3","key":"562_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JAD-2009-1075","volume":"17","author":"S Jesse","year":"2009","unstructured":"Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer\u2019s disease and Creutzfeldt-Jakob disease. J Alzheimers Dis. 2009;17(3):541\u201351. https:\/\/doi.org\/10.3233\/JAD-2009-1075.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"562_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JAD-2010-090649","volume":"21","author":"JJ van Eijk","year":"2010","unstructured":"van Eijk JJ, van Everbroeck B, Abdo WF, Kremer BP, Verbeek MM. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis. 2010;21(2):569\u201376. https:\/\/doi.org\/10.3233\/JAD-2010-090649.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"562_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2015","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Wald\u00f6 M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2015;3(1):12\u201320. https:\/\/doi.org\/10.1002\/acn3.266.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"562_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258\u201361. https:\/\/doi.org\/10.1111\/jnc.13399.","journal-title":"J Neurochem"},{"issue":"7","key":"562_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"562_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","volume":"89","author":"D Alcolea","year":"2017","unstructured":"Alcolea D, Vilaplana E, Su\u00e1rez-Calvet M, Ill\u00e1n-Gala I, Blesa R, Clarim\u00f3n J, et al. CSF sAPP\u03b2, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000004088.","journal-title":"Neurology."},{"issue":"1","key":"562_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","volume":"12","author":"F Llorens","year":"2017","unstructured":"Llorens F, Th\u00fcne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83. https:\/\/doi.org\/10.1186\/s13024-017-0226-4.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"562_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/acn3.629","volume":"5","author":"M Del Campo","year":"2018","unstructured":"Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018;5(10):1163\u201375. https:\/\/doi.org\/10.1002\/acn3.629.","journal-title":"Ann Clin Transl Neurol."},{"issue":"1","key":"562_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-018-0361-3","volume":"10","author":"RW Paterson","year":"2018","unstructured":"Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther. 2018;10(1):32. https:\/\/doi.org\/10.1186\/s13195-018-0361-3.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"562_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89(3):239\u201347. https:\/\/doi.org\/10.1136\/jnnp-2017-317138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"562_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jnnp-2018-318868","volume":"90","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4\u201310. https:\/\/doi.org\/10.1136\/jnnp-2018-318868.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"562_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481\u20138. https:\/\/doi.org\/10.3233\/JAD-180325.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"562_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jneuroim.2008.03.021","volume":"197","author":"S Sotgiu","year":"2008","unstructured":"Sotgiu S, Musumeci S, Marconi S, Gini B, Bonetti B. Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer\u2019s disease brains. J Neuroimmunol. 2008;197(1):70\u20133. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.03.021.","journal-title":"J Neuroimmunol"},{"issue":"40","key":"562_CR26","doi-asserted-by":"publisher","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680\u20135.","journal-title":"J Biol Chem"},{"issue":"8","key":"562_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/sj.gene.6364025","volume":"4","author":"L Malaguarnera","year":"2003","unstructured":"Malaguarnera L, Simpor\u00e8 J, Prodi DA, Angius A, Sassu A, Persico I, et al. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. Genes Immun. 2003 Dec;4(8):570\u20134.","journal-title":"Genes Immun"},{"issue":"4","key":"562_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036333","volume":"7","author":"C Jansen","year":"2012","unstructured":"Jansen C, Parchi P, Capellari S, Ibrahim-Verbaas CA, Schuur M, Strammiello R, et al. Human prion diseases in the Netherlands (1998-2009): clinical, genetic and molecular aspects. PLoS One. 2012;7(4):e36333. https:\/\/doi.org\/10.1371\/journal.pone.0036333.","journal-title":"PLoS One"},{"issue":"4","key":"562_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00401-012-1002-8","volume":"124","author":"P Parchi","year":"2012","unstructured":"Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol. 2012;124(4):517\u201329. https:\/\/doi.org\/10.1007\/s00401-012-1002-8.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"562_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00401-017-1683-0","volume":"133","author":"F Lattanzio","year":"2017","unstructured":"Lattanzio F, Abu-Rumeileh S, Franceschini A, Kai H, Amore G, Poggiolini I, et al. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A\u03b242 levels. Acta Neuropathol. 2017;133(4):559\u201378. https:\/\/doi.org\/10.1007\/s00401-017-1683-0.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"562_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W","volume":"46","author":"P Parchi","year":"1999","unstructured":"Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(2):224\u201333.","journal-title":"Ann Neurol"},{"key":"562_CR32","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737. https:\/\/doi.org\/10.1038\/srep38737.","journal-title":"Sci Rep"},{"issue":"2","key":"562_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3233\/JAD-180409","volume":"66","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, Polischi B, Oppi F, Poda R, et al. Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J Alzheimers Dis. 2018;66(2):551\u201363. https:\/\/doi.org\/10.3233\/JAD-180409.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"562_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311. https:\/\/doi.org\/10.1007\/s00401-011-0910-3.","journal-title":"Acta Neuropathol"},{"issue":"Pt 9","key":"562_CR35","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain."},{"issue":"11","key":"562_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology."},{"issue":"5","key":"562_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria forthe diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology."},{"issue":"3\u20134","key":"562_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3\u20134):153\u201374. https:\/\/doi.org\/10.1080\/21678421.2016.1267768.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"562_CR39","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"issue":"2","key":"562_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acn3.697","volume":"6","author":"S Baiardi","year":"2018","unstructured":"Baiardi S, Abu-Rumeileh S, Rossi M, Zenesini C, Bartoletti-Stella A, Polischi B, Capellari S, Parchi P. Antemortem CSF A\u03b242\/A\u03b240 ratio predicts Alzheimer\u2019s disease pathology better than A\u03b242 in rapidly progressive dementias. Ann Clin Transl Neurol. 2018 Dec 14;6(2):263\u201373. https:\/\/doi.org\/10.1002\/acn3.697.","journal-title":"Ann Clin Transl Neurol."},{"issue":"3","key":"562_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer\u2019s Association quality control program. Alzheimers Dement. 2013;9(3):251\u201361. https:\/\/doi.org\/10.1016\/j.jalz.2013.01.010.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"562_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-181012","volume":"68","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Giannini G, Polischi B, Albini-Riccioli L, Milletti D, Oppi F, et al. Revisiting the cerebrospinal fluid biomarker profile in idiopathic Normal pressure hydrocephalus: the Bologna Pro-Hydro Study. J Alzheimers Dis. 2019;68(2):723\u201333. https:\/\/doi.org\/10.3233\/JAD-181012.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"562_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","volume":"10","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P, et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018;10(1):3. https:\/\/doi.org\/10.1186\/s13195-017-0331-1.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"562_CR44","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1038\/s41598-017-10922-w","volume":"7","author":"A Franceschini","year":"2017","unstructured":"Franceschini A, Baiardi S, Hughson AG, McKenzie N, Moda F, Rossi M, et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci Rep. 2017;7(1):10655. https:\/\/doi.org\/10.1038\/s41598-017-10922-w.","journal-title":"Sci Rep"},{"issue":"4","key":"562_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000490920","volume":"18","author":"L Martinez-Merino","year":"2018","unstructured":"Martinez-Merino L, Iridoy M, Galbete A, Rold\u00e1n M, Rivero A, Acha B, Ir\u00fan P, Canosa C, Pocov\u00ed M, Mendioroz M, Jeric\u00f3 I. Evaluation of chitotriosidase and CC-chemokine ligand 18 as biomarkers of microglia activation in amyotrophic lateral sclerosis. Neurodegener Dis. 2018;18(4):208\u201315. https:\/\/doi.org\/10.1159\/000490920.","journal-title":"Neurodegener Dis"},{"issue":"3","key":"562_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000094870","volume":"22","author":"TW Chow","year":"2006","unstructured":"Chow TW, Hynan LS, Lipton AM. MMSE scores decline at a greater rate in frontotemporal degeneration than in AD. Dement Geriatr Cogn Disord. 2006;22(3):194\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"562_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.dadm.2015.11.001","volume":"1","author":"YA Pijnenburg","year":"2015","unstructured":"Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1(4):505\u201312. https:\/\/doi.org\/10.1016\/j.dadm.2015.11.001.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"14","key":"562_CR48","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","volume":"90","author":"LHH Meeter","year":"2018","unstructured":"Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, et al. Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000005261.","journal-title":"Neurology."},{"issue":"7","key":"562_CR49","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00415-006-0472-9","volume":"254","author":"P Sanchez-Juan","year":"2007","unstructured":"Sanchez-Juan P, S\u00e1nchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrov\u00e1 E, et al. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol. 2007;254(7):901\u20136.","journal-title":"J Neurol"},{"issue":"1","key":"562_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","volume":"14","author":"M Querol-Vilaseca","year":"2017","unstructured":"Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Mart\u00edn-Paniello C, Clarimon J, Belbin O, et al. YKL-40 (chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118. https:\/\/doi.org\/10.1186\/s12974-017-0893-7.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"562_CR51","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1007\/s12035-017-0522-6","volume":"55","author":"L Iaccarino","year":"2018","unstructured":"Iaccarino L, Moresco RM, Presotto L, Bugiani O, Iannaccone S, Giaccone G, et al. An in vivo (11) C-(R)-PK11195 PET and in vitro pathology study of microglia activation in Creutzfeldt-Jakob disease. Mol Neurobiol. 2018;55(4):2856\u201368.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"562_CR52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u201376. https:\/\/doi.org\/10.15252\/emmm.201506123.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"562_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383. https:\/\/doi.org\/10.1038\/s41591-018-0304-3.","journal-title":"Nat Med"},{"issue":"5","key":"562_CR54","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15(5):644\u201354. https:\/\/doi.org\/10.1016\/j.jalz.2019.01.004.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"562_CR55","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623\u201336. https:\/\/doi.org\/10.1002\/acn3.325.","journal-title":"Ann Clin Transl Neurol."},{"issue":"1","key":"562_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","volume":"79","author":"P Weydt","year":"2016","unstructured":"Weydt P, Oeckl P, Huss A, M\u00fcller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152\u20138. https:\/\/doi.org\/10.1002\/ana.24552.","journal-title":"Ann Neurol"},{"issue":"2","key":"562_CR57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000362164","volume":"4","author":"C Ros\u00e9n","year":"2014","unstructured":"Ros\u00e9n C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra. 2014;4(2):297\u2013304. https:\/\/doi.org\/10.1159\/000362164.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"562_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2010\/610613","volume":"2010","author":"Niklas Mattsson","year":"2010","unstructured":"Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer\u2019s disease. Int J Alzheimers Dis. 2010. https:\/\/doi.org\/10.4061\/2010\/610613.","journal-title":"International Journal of Alzheimer's Disease"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0562-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:16:29Z","timestamp":1609287389000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0562-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0562-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,31]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was provided by study participants or their next of kin. The study protocol was approved by the ethics committees of \u201cArea Vasta Emilia Centro\u201d (approval number CE-AVEC: 18025, 113\/2018\/OSS\/AUSLBO) and Ulm University (approval number 20\/10).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}